证据
- What are the effects of topical mosquito repellents for preventing malaria in people living in endemic areas?
- How do drugs for the prevention of malaria in pregnant women affect fetal and infant outcomes?
- How does rapid diagnostic testing for malaria compare with clinical diagnosis for treating people with fever in malaria endemic settings?
- What are the effects of artesunate versus quinine in people with severe malaria?
- How does dihydroartemisinin-piperaquine compare with artesunate-containing regimens in people with uncomplicated falciparum malaria?
- Does combining artesunate with mefloquine have any benefit over mefloquine alone for treating uncomplicated malaria?
- How does dihydroartemisinin-piperaquine compare with artemether-lumefantrine in people with uncomplicated falciparum malaria?
- What are the benefits and harms of primaquine for reducing transmission of Plasmodium falciparum?
- How does artemether compare with artesunate or quinine in adolescents and adults with severe malaria?
- How does artemether compare with quinine in children with severe malaria?
- How do different artemisinin-based therapies compare for the treatment of uncomplicated Plasmodium vivax malaria?
- How do artemisinin-based therapies (ACT) compare with non-artemisinin-based (non-ACT) regimens for the treatment of uncomplicated Plasmodium vivax malaria?
- Can tafenoquine prevent relapse in people with Plasmodium vivax malaria?
使用此内容应接受我们的免责声明。
